RADIANT-3 Trial: Everolimus for Patients With pNETs OncLive The utilization of the mTOR inhibitor everolimus as a treatment for patients with pancreatic neuroendocrine tumors (pNET) has increased since the FDA first approved the drug in this space in 2011, based on findings from the RADIANT-3 study. |
